• Tuesday December 9, 2008, 7:00 am EST

• Thursday December 4, 2008, 11:06 am EST

"I sincerely thank our shareholders who demonstrated their strong support by exercising their warrants. We now have the financial resources to execute on all of the necessary milestones to get our fibrin sealant into the clinic in Q1-09. This financing significantly reduces the financial risk. All of our time and attention will be focused on execution and getting a green light from the FDA to enter clinical trials." said Joseph Galli, Chairman and CEO of Haemacure.

Manufacturing Facility

On June 4th, Haemacure began fractionating plasma in its new facility in Sarasota, Florida. It is on-schedule and on-budget to produce fibrin sealant clinical lots during Q3-08 and to file an amendment to its existing IND with the U.S. FDA during Q4-08.

Haemacure's fractionation facility is the first and only U.S.-based manufacturing facility for fibrin sealant destined for the U.S. market and this is of significant strategic value.

Fibrin Sealant Pivotal Clinical Trials

The safety of Haemacure's lead product candidate, all-human fibrin sealant, was demonstrated in past clinical trials as no serious adverse events related to the product were reported. The efficacy of the product was also significantly superior to the standard of care used in the control group.

New Preclinical Study in Adhesion Prevention

Encouraged by the positive results of the preclinical study Haemacure conducted on the efficacy of its all-human fibrin sealant in preventing the formation of post-surgical adhesions, Haemacure will sponsor a second study for the same application, in a slightly different model.

Market Opportunities

Haemacure is currently pursuing business development opportunities in six market segments where fibrin sealant has application, beyond its core haemostasis segment. These are wound management, adhesion prevention, regenerative medicine, drug delivery, in combination with biomaterials, and cosmetics. All these segments represent major growth opportunities that Haemacure will leverage.

Haemacure is pursuing strategic partnerships for the development of the proteins it has identified in one of its two plasma fractions: albumin, alpha-1 anti-trypsyn, immunoglobulin and plasminogen.

About Haemacure

Haemacure Corporation is a specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medicine, drug delivery and combinations with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates a manufacturing facility in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

For further information

Haemacure Corporation: Joseph Galli, Chairman and CEO, (514) 990-7074, jgalli@pentor.com

Diane Roch, Director, Communications, (514) 282-3350 ext. 27, Cell: (514) 952-3350, droch@haemacure.ca

Gilles Lemieux, Secretary, (514) 282-3350 ext. 22, Cell: (514) 968-1382, glemieux@haemacure.ca

www.haemacure.com

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical hemostats. Haemacure's lead product candidate,
Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase
III clinical trials during the first quarter of 2009. Haemacure's second
product candidate is thrombin, a component of its fibrin sealant, now in
preclinical stage. Follow-on development will focus on surgical hemostats,
wound healing, adhesion prevention, regenerative medecine, drug delivery and
combination with biomaterials. Haemacure has discovered eleven additional
specialty proteins and enzymes in one if its two plasma fractions and seeks to
advance these proteins and enzymes through partnerships with pharmaceutical
and biotechnology companies. Haemacure operates offices in Sarasota, Florida
through a wholly-owned subsidiary. The Corporation is traded under stock
symbol HAE on the TSX.

For further information:

Haemacure Corporation:

Joseph Galli
Chairman and CEO
(514) 990-7074
jgalli@haemacure.ca
www.haemacure.com

Diane Roch,
Director, Communications
(514) 282-3350 ext. 27,
Cell.: (514) 952-3350,
droch@haemacure.ca/

Montréal, Québec, le 4 juin 2008 – Corporation Haemacure (TSX:HAE), une société de Montréal de spécialités bio-thérapeutiques développant des produits protéiques de grande valeur dérivés du plasma humain pour commercialisation, annonce qu’elle a commencé à traiter du plasma dans sa nouvelle usine de fractionnement pour la production de sa colle de fibrine exclusive en vue des essais cliniques clés de Phase II/phase III, et ensuite de son lancement commercial.

Haemacure a atteint une étape importante cette semaine en commençant le fractionnement de plasma dans sa nouvelle usine. Haemacure confirme aussi qu’elle respecte son échéancier et son budget pour la production de matériel clinique et l’amendement de sa demande de drogue nouvelle de recherche (« IND ») auprès de la Food and Drug Administration des États-Unis, de façon à commencer les essais cliniques au premier trimestre de 2009.

La nouvelle usine de fractionnement emploiera la technologie de bio-traitement de contenants de plastique jetables Hynetics®. Ceci a permis des économies importantes en dépenses en immobilisation et permettra aussi des économies importantes en coûts d’exploitation, en comparaison avec une usine employant un équipement en acier inoxydable. L’emploi de cette technologie minimisera aussi les risques de contamination croisée entre les lots de production.

« Maintenant que notre usine de fractionnement est opérationnelle et que nous avons commencé à traiter du plasma, Haemacure est vraiment engagée dans sa transformation d’une société de développement en société manufacturière. » a déclaré M. Joseph Galli, président du conseil et chef de la direction d’Haemacure. « La disponibilité prochaine de matériel clinique permettra à Haemacure de poursuivre son programme clinique en hémostase et de l’étendre dans d’autres indications, tel la prévention des adhérences. » M. Galli a-t-il conclu.

Au sujet d’Haemacure

Corporation Haemacure est une société de spécialités bio-thérapeutiques concentrée sur le développement et la commercialisation de protéines humaines thérapeutiques de grande valeur. Ses activités de recherche et développement de produits reposent sur sa technologie exclusive d’extraction de protéines plasmatiques, pour développer des produits de prochaine génération, dont des produits hémostatiques chirurgicaux. Le produit candidat principal d’Haemacure est une colle de fibrine humaine, Hemaseel^®HMN, prévue entrer en essais clinique clés de phase II/phase III au premier trimestre de 2009. Son second produit candidat est la thrombine, un élément de la colle de fibrine, présentement au stade préclinique. Les développements futurs porteront sur des produits hémostatiques chirurgicaux, la guérison des plaies, la prévention des adhérences, la médecine régénérative, la libération contrôlée des médicaments et des combinaisons avec des biomatériaux. Haemacure a identifié onze spécialités protéiques et enzymatiques additionnelles dans une de ses deux fractions plasmatiques et cherche à les développer en association avec des sociétés pharmaceutiques ou biotechnologiques. Haemacure exploite aussi une filiale à part entière à Sarasota, en Floride. Les actions de la société sont inscrites à la cote de la Bourse de Toronto sous le symbole HAE.

Énoncés prospectifs

Certains énoncés contenus dans ce communiqué de presse sont de nature prospective. Tels énoncés, reposant sur les attentes présentes de la direction, comprennent de nombreux risques et incertitudes inhérents, connus et inconnus. Des exemples de risques connus sont : l’impact de l’état général de l’économie, l’état général de l’industrie de la biotechnologie, les résultats des essais cliniques, les changements dans l’environnement réglementaire des juridictions où Haemacure fait affaire, la volatilité des marchés boursiers, les variations de coûts, et des changements dans l’environnement concurrentiel dus à des consolidations ou autres événements. En conséquence, les résultats futurs réels pourront présenter des différences importantes par rapport aux résultats attendus exprimés dans les énoncés prospectifs. Haemacure nie toute intention ou obligation de mettre ces énoncés à jour.

Pour information :

Corporation Haemacure

Joseph Galli
Président du conseil et chef de la direction
(514) 990-7074
jgalli@haemacure.ca

Diane Roch
Directrice, communications et relations avec les investisseurs
(514) 282-3350 ext. 27
Cel.: (514) 952-3350
droch@haemacure.ca

www.haemacure.com

MONTREAL, June 4 - Haemacure Corporation (TSX: HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announces that it has started processing plasma in its new fractionation facility for the production of its proprietary all-human fibrin sealant for pivotal Phase II/Phase III clinical trials, leading to commercial launch.

Haemacure has reached an important milestone this week with the commencement of plasma fractionation in its new manufacturing facility. Haemacure also confirms that it is on schedule and on budget to produce clinical material during the third quarter of 2008 and file an amendment to its existing IND with the U.S. Food and Drug Administration during the fourth quarter of 2008, in order to begin clinical trials in the first quarter of 2009.

The new fractionation facility incorporates the Hynetics(R) single-use bio-processing plastic containers technology, which has resulted in significant savings in capital expenditures and will also result in significant savings in operating costs, as compared to a stainless steel facility. The use of this technology also minimizes the risks of cross-contamination between production batches.

"Now that our fractionation facility is operational and that we have started processing plasma, Haemacure is truly engaged in its transformation from a development to a manufacturing company." said Joseph Galli, Chairman and CEO of Haemacure. "The upcoming availability of clinical material will enable Haemacure to pursue its clinical plans in hemostasis and to expand into additional indications, such as adhesion prevention." concluded Mr. Galli.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Contacts

Haemacure Corporation:

Joseph Galli
Chairman and CEO
(514) 990-7074
jgalli@haemacure.ca

Diane Roch
Director Communications and Investor Relations
(514) 282-3350 ext. 27
Cel.: (514) 952-3350
droch@haemacure.ca

www.haemacure.com

Montréal, le 2 juin 2008 – Corporation Haemacure (TSX:HAE), une société de spécialités bio-thérapeutiques de Montréal développant des produits protéiques de grande valeur dérivés du plasma humain pour commercialisation, fait une mise à jour sur son financement et publie les résultats du deuxième trimestre.

Financement

Selon les engagements reçus à ce jour de la part d’actionnaires clés d’exercer leurs bons de souscription de série B, Haemacure est bien placée pour rencontrer son objectif de commencer les essais cliniques clés de phase II/phase III pour sa colle de fibrine. La société respecte son échéancier et son budget pour la construction de son usine.

« Nous sommes très reconnaissants et encouragés par le fort appui que nous avons reçu de nos actionnaires importants, Firebird Management et Pinetree Capital, tel que démontré par l’exercice de leurs bons de souscription de série B. » a déclaré M. Joseph Galli, président du conseil et chef de la direction. « Cet appui, associé à la nomination récente de Reinaldo Diaz à notre conseil d’administration et l’embauche de cadres supérieurs à l’usine, sont des éléments de notre stratégie de création de valeur qui fera d’Haemacure un joueur important sur la scène globale. » a conclu M. Galli.

Résultats du trimestre

Les revenus se sont élevés à 28 368 $, comparé à 24 757 $ pour le même trimestre l’an dernier. Les revenus proviennent exclusivement de la vente d’applicateurs de colle de fibrine patrimoniaux. Les dépenses d’exploitation se sont élevées à 2,5 millions $, comparé à 1,3 million $ pour le même trimestre l’an dernier, résultat de l’augmentation importante des activités reliées à la construction de l’usine, au développement de produit, à la préparation des essais cliniques et à des charges non-récurrentes. La perte nette consolidée pour le trimestre s’est élevée à 2,5 millions $, ou 0,02 $ par action, comparé à
1,3 million $, ou 0,01 par action, pour le même trimestre l’an dernier.

Situation financière

Les espèces, quasi-espèces et placements temporaires s’élevaient à 3,6 millions $ le 30 avril 2008, comparé à 7,6 millions $ le 31 octobre 2007.

Au sujet d’Haemacure

Corporation Haemacure est une société de spécialités bio-thérapeutiques concentrée sur le développement et la commercialisation de protéines humaines thérapeutiques de grande valeur. Ses activités de recherche et développement de produits reposent sur sa technologie exclusive d’extraction de protéines plasmatiques, pour développer des produits de prochaine génération, dont des produits hémostatiques chirurgicaux. Le produit candidat principal d’Haemacure est une colle de fibrine humaine, Hemaseel^®HMN, prévue entrer en essais clinique clés de phase II/phase III au premier trimestre de 2009. Son second produit candidat est la thrombine, un élément de la colle de fibrine, présentement au stade préclinique. Les développements futurs porteront sur des produits hémostatiques chirurgicaux, la guérison des plaies, la prévention des adhérences, la médecine régénérative, la libération contrôlée des médicaments et des combinaisons avec des biomatériaux. Haemacure a identifié onze spécialités protéiques et enzymatiques additionnelles dans une de ses deux fractions plasmatiques et cherche à les développer en association avec des sociétés pharmaceutiques ou biotechnologiques. Haemacure a son siège à Montréal, au Québec, et elle exploite aussi une filiale à part entière à Sarasota, en Floride. Les actions de la société sont inscrites à la cote de la Bourse de Toronto sous le symbole HAE.

Énoncés prospectifs

Certains énoncés contenus dans ce communiqué de presse sont de nature prospective. Tels énoncés, reposant sur les attentes présentes de la direction, comprennent de nombreux risques et incertitudes inhérents, connus et inconnus. Des exemples de risques connus sont : l’impact de l’état général de l’économie, l’état général de l’industrie de la biotechnologie, les résultats des essais cliniques, les changements dans l’environnement réglementaire des juridictions où Haemacure fait affaire, la volatilité des marchés boursiers, les variations de coûts, et des changements dans l’environnement concurrentiel dus à des consolidations ou autres événements. En conséquence, les résultats futurs réels pourront présenter des différences importantes par rapport aux résultats attendus exprimés dans les énoncés prospectifs. Haemacure nie toute intention ou obligation de mettre ces énoncés à jour.

Faits saillants financiers

(non vérifiés)

Trimestres terminés les

Pour information :

Corporation Haemacure

Joseph Galli
Chairman and CEO
Tel: 514-990-7074
jgalli@haemacure.ca

www.haemacure.com

Diane Roch
Director Communications
(514) 282-3350 ext. 27
Cel.: (514) 952-3350
droch@haemacure.ca

www.haemacure.com

Financing

As a result of the commitments Haemacure has received to-date from key shareholders to exercise their Series B warrants, the Corporation is well positioned to meet its objective of commencing the fibrin sealant pivotal
Phase II/Phase III clinical trials. The Corporation remains on schedule and on budget with the construction of its manufacturing facility.

“We are very appreciative and encouraged by the strong support we have received from our major shareholders, Firebird Management and Pinetree Capital, as demonstrated through the exercise of their Series B warrants.” said Joseph Galli, Chairman and CEO of Haemacure. “This support, coupled with the recent addition of Reinaldo Diaz to our Board of Directors and the hiring of senior managers at our facility, are elements of our value creation strategy that will make Haemacure a significant player on the global scale.” concluded Mr. Galli.

Second Quarter Results

Revenues amounted to $28,368, as compared to $24,757 for the same quarter last year. Revenues are exclusively derived from the sale of legacy fibrin sealant application devices. Operating expenses amounted to $2.5 million, as compared to $1.3 million for the same quarter last year. The increase is mainly related to the hiring of personnel, consulting expenses, supplies for the laboratory and the manufacturing facility and unusual charges. The consolidated net loss for the quarter amounted to $2.5 million, or $0.02 per share, as compared to $1.3 million, or $0.01 per share, for the same quarter last year.

Financial Position

Cash, cash equivalents and temporary investments amounted to $3.6 million as of April 30, 2008, as compared to $7.6 million as at October 31, 2007.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel^®HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Financial Highlights

(unaudited)

Quarters ended

For Information:

Contacts

Joseph Galli
Chairman and CEO
Tel: 514-990-7074
jgalli@haemacure.ca

www.haemacure.com

Diane Roch
Director Communications
(514) 282-3350 ext. 27
Cel.: (514) 952-3350
droch@haemacure.ca

www.haemacure.com

http://www.agoracom.com/executive/08...

Blood plasma. The lure of therapeutic proteins has caused the price of this blood derivative to climb.

By Carole Le Hirez > carole.lehirez@transcontinental.ca

Joseph Galli, of Haemacure: “With human plasma, we eliminate certain
problems that bovine products present. It’s purer and safer.”

In the future, the lives of millions of people all over the world will be saved thanks to protein-based medicines. These molecules, which directly target the cause of disease in the organism, open the door to a revolutionary approach in medicine, comparable to the one Pasteur introduced with his rabies vaccine. Yet numerous challenges confront this promising industry: research funding, the availability
of the blood plasma from which the raw material is drawn, and the high price of treatments which are slowing expected progress.

Human plasma contains a number of proteins that are used to manufacture roughly 20 therapeutic products.

According to a 2005 study conducted for Héma-Québec, plants fractionating plasma proteins treat over 25 million litres of plasma every year worldwide. Sales in the plasma-derived protein market were nearly $5 billion in 2005.

Fractionation plants
Among the most valuable proteins extracted from plasma are albumin, which represents 28% of this market, and gamma globulins, which represent two thirds of plasma product sales.

Haemacure of Montreal extracts fibrinogen and thrombin from human plasma, the two proteins used in manufacturing its fibrin glue, which prevents post-operative adhesion. Fibrin glue and thrombin are its two flagship products.

“With human plasma, we eliminate certain problems that bovine products present. It’s purer and safer,” said Joseph Galli, Haemacure’s Chief Executive Officer.

Like many others, the company looks to the United States for its supplies. There are approximately 70 fractionating plants in the world. The U.S. has the largest number, with an average processing capacity of 1.1 million litres per plant, according to the Marketing Research Bureau. Europe comes second, and
Asia rounds out the leading three. Approximately 60 grams of protein can be extracted from a litre of plasma.

The growth in demand for biopharmaceutical proteins is putting pressure on plasma of human origin, whose availability is limited because of increasingly stringent selection criteria for donors, and tightened requirements on collection and screening methods.

“Over the past few years, the price of a litre of plasma went from $125 to $200. The market should stabilize over the next two years, because there has been consolidation in the industry. In 2010, available volume should rise,” predicted Galli.

High costs
It takes approximately 18 months for a blood sampling site to be certified by the Food and Drug Administration, and another 18 months for it to accumulate operating reserves.

The budget dedicated to plasma-derived products in Canada is approximately $274 million per year and growing. Though the country is self-sufficient in terms of plasma for transfusion purposes, it collects only a third of the plasma it needs for fractionation.

At Héma-Québec, surplus plasma not used for medical purposes is sent to an American fractionator, which returns the isolated proteins. The organization thus covers 20 percent of its total needs in immunoglobulins and 75 percent of its needs in albumin, proteins that are particularly used in research.

There is only one fractionating plant in Canada, in Winnipeg. This hyperspecialized company is dedicated to a single molecule, anti-D immunoglobulin, used to avoid certain types of miscarriages.

“Building a fractionating plant is very expensive, from one to two billion,” said Jean Lapierre, Director, Stable Products, at Héma-Québec. “But we’re seeing a consolidation of the sector. A smaller number of players are producing ever-increasing volumes. This is going to be reflected in prices.”

Blood plasma
A component of blood, plasma serves to transport blood cells and hormones throughout the body. It is 90 percent water. It contains mineral salts and organic compounds (nutrients, urea, etc.) and proteins, such as fibrinogen (a coagulation protein), globulins and albumin.

MONTREAL, May 20 - Haemacure Corporation (TSX: HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announces that Gilles Lemieux, Corporate Secretary, will present at Busines$ Meets Finance at the Montreal Sheraton Centre on May 20, 2008 at 2:35 p.m.

About Busines$ Meets Finance

Busines$ Meets Finance is a conference organized by the Toronto Stock Exchange and the Montreal law firm Heenan Blaikie designed to foster alliances between investors and Quebec small and medium size businesses. The conference will be attended by leading North American private equity and merchant banking firms from the United States and the rest of Canada.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Contacts

Haemacure Corporation: Gilles Lemieux
Secretary
(514) 282-3350
ext. 22
Cel: (514) 968-1382
glemieux@haemacure.ca

Diane Roch
Director
Communications
(514) 282-3350
ext. 27
Cel.: (514) 952-3350
droch@haemacure.ca

www.haemacure.com

Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference

MONTREAL, May 16 - Haemacure Corporation (TSX: HAE), a specialty bio-therapeutics company developing high-value human proteins for commercialization, announced today that its Chairman of the Board and Chief Executive Officer, Joseph Galli, will present at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20, 2008 in the Zephyr Room at Le Méridien Beach Plaza Hotel in Monte Carlo, Monaco, beginning at 1:40 p.m Central European Summer Time (7:40 a.m. Eastern Daylight Time).

Rodman & Renshaw will webcast the audio portion of the presentation and post the associated slides via its website at www.rodmanandrenshaw.com, hosted by Wall Street Webcasting. To access the live broadcast via internet in listen-only mode, or the subsequently archived recording, simply cut and paste the following link directly into your web browser: http://www.wsw.com/webcast/rrshq13/h...

Please visit the site at least five minutes prior to start time for instructions.

About Rodman & Renshaw's Annual Global Healthcare Conference

The conference will include presentations by over 200 companies, as well as experts from the medical, scientific and investment communities. Details regarding the conference can be obtained at www.rodmanandrenshaw.com

Haemacure also announced today the resignation of Mr. Neil Weiner from the Board of Directors of the Company. "On behalf of the Board and management team, I wish to thank Neil for his tremendous contribution and dedication to Haemacure" commented Joseph Galli, Chairman and CEO of Haemacure.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Contacts

Haemacure Corporation: Joseph Galli
Chairman and CEO
(514) 990-7074
jgalli@haemacure.ca

Diane Roch
Director
Communications
(514) 282-3350 ext. 27
Cell.: (514) 952-3350
droch@haemacure.ca

www.haemacure.com

MONTREAL, May 15 - Haemacure Corporation (TSX: HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announced today the appointment of Reinaldo M. Diaz as a new member of the Board of Directors' of the Company.

"I am very pleased to welcome Reinaldo to our Board of Directors" said Joseph Galli, Haemacure's Chairman of the Board and Chief Executive Officer. "His experience and know-how in the biopharmaceutical industry and asset management field will certainly be beneficial to Haemacure's continued growth, development and operations for years to come" concluded Mr. Galli.

About Reinaldo M. Diaz

Mr. Diaz has over 25 years of experience in the biopharmaceutical industry. He currently serves as a Managing Director of Celtic Pharma Management, L.P. a global equity firm focused on the pharmaceutical industry. Prior to joining Celtic Pharma, Mr. Diaz was Managing Member and Co-Founder of D&A Capital Management, LLC ("D&A Capital"), a firm focused on asset management and providing advisory services to companies in the healthcare sector, particularly biopharmaceutical companies. From 1993 to 1996, Reinaldo was Managing Director and Head of the Healthcare group at Schroder Wertheim & Co., Inc. In that capacity, he was responsible for establishing and expanding Schroder Wertheim's investment banking presence in the healthcare industry. From 1981 to 1993, Reinaldo was with PaineWebber, Inc. During his tenure at PaineWebber, he was a key member of the PaineWebber Healthcare Investment Banking Group and of PaineWebber Development Corporation. He became President of PaineWebber Development Corporation in 1990, having been a managing director prior to that time.

"I am pleased to join Haemacure's Board of Directors and look forward to working with Joseph Galli, Haemacure's management team and other board members to help Haemacure achieve its product development and commercial goals," said Mr. Diaz.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Contacts

Haemacure Corporation:

Joseph Galli
Chairman and CEO
(514) 990-7074
jgalli@haemacure.ca

www.haemacure.com

Diane Roch
Director
Communications
(514) 282-3350 ext. 27
Cell.: (514) 952-3350
droch@haemacure.ca

Haemacure financing receives shareholder consent - Series B Warrants are amended

HAE:TSX

MONTREAL, May 14 - Haemacure Corporation (TSX: HAE) announces that it has obtained the consent required from its shareholders to commence implementing a financing strategy designed to get back into the clinic for the pivotal Phase II/Phase III clinical trials for its next generation, all-human fibrin sealant during Q1-2009. The strategy involves the amendment of the terms and conditions of 62.5 million outstanding Series B common share purchase warrants issued by Haemacure by way of private placement in January 2007.

"I am very pleased with the level of support that our shareholders have demonstrated by approving this amendment to the Series B Warrants, thus enabling Haemacure to finance operations with the least dilution possible", said Mr. Joseph Galli, Chairman & CEO of Haemacure. "Participants in our January 2007 private placement indicated their willingness to further finance the Company based on Haemacure achieving certain value creation milestones. Haemacure is on-time and on budget to meeting the three milestones necessary to getting back into the clinic for its next generation fibrin sealant by Q1-2009. These milestones are the commissioning of the manufacturing facility (IQ/OQ) by mid '08, the production of clinical material by Fall '08, and the approval of an amendment to the IND currently open with the FDA (end '08)", continued Mr. Galli. "Concurrent with our getting back into the clinic with our fibrin sealant, we are working on strategic partnership opportunities that will enable Haemacure to rapidly become a significant player on a global scale" concluded Mr. Galli.

Each of the Series B Warrants currently entitles the holder to acquire one additional common share of Haemacure at a price of $0.20 for a period of five years from the date of issuance. As a result of the amendment, if Series B Warrants are exercised during a period of ten business days commencing on May 29, 2008 and ending on June 12, 2008, Haemacure will issue to the holder, with each Haemacure common share purchased upon the exercise of Series B Warrants, one additional common share purchase warrant. Each additional warrant will entitle the holder to acquire one additional common share of Haemacure at a price of $0.25 until April 18, 2013.

If Series B Warrants are not exercised during the ten business-day period, the holder will not be entitled to receive the additional warrants upon the subsequent exercise of Series B Warrants. Holders of Series B Warrants who do not exercise them during the ten business-day period will retain the right to exercise the Series B Warrants in accordance with their original terms and conditions.

If all of the Series B Warrants are exercised during the ten business-day period, and all of the additional warrants are also exercised, Haemacure will issue a total of 62,500,000 common shares upon the exercise of the additional warrants, representing additional dilution of 38.2% when compared to the 163,800,917 common shares of Haemacure currently issued and outstanding.

The effective date of the amendment will be on the tenth business day after the issuance of this press release. The amendment to the terms and conditions of the Series B Warrants has been approved by the Toronto Stock Exchange, which required that the amendment be approved by Haemacure's shareholders, other than "insiders" of Haemacure who hold Series B Warrants. Haemacure relied on an exemption, set out in section 604(d) of the TSX Company Manual, from the requirement to call a shareholders' meeting to consider the amendment. Pursuant to the exemption, Haemacure provided written evidence to the TSX that holders of more than 50% of Haemacure's common shares (other than "insiders" of Haemacure who hold Series B Warrants) are familiar with the terms of the amendment and in favor of it. A total of nine "insiders" of Haemacure hold Series B Warrants. The Schedule annexed to this press release sets out: (a) the names and positions of the "insiders" who hold Series B Warrants; and (b) assuming such "insiders" exercise all Series B Warrants and additional warrants held by them, the number and percentage of common shares of Haemacure that each will own.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medicine, drug delivery and combinations with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

    
                                   SCHEDULE


                                                       Number of   Percentage
                             Number of    Number of       Common    of Common
                                Shares     Series B     Shares -     Shares -
    Name of Insider             Held /     Warrants         Post         Post
    and Position            Controlled         Held     Exercise     Exercise
    ---------------         ----------    ---------    ---------   ----------
    Firebird Global Master
    Fund II, Ltd
    Holder of more than
    10% of outstanding
    shares                  15,000,000    7,500,000   30,000,000         10.4

    Firebird Global Master
    Fund, Ltd
    Holder of more than 10%
    of outstanding shares   10,000,000    5,000,000   20,000,000          6.9

    Galli, Joseph
    Officer and Director     2,216,300      650,000    3,516,300          1.2

    Paquin, Marc
    Officer and Director     1,947,000      250,000    2,447,000          0.8

    Johnson, Wayne
    Director                   415,770      175,000      765,770          0.3

    Alary, Pierre
    Director                   314,000      125,000      564,000          0.2

    Baehr, Paul
    Director                   265,000      125,000      515,000          0.2

    Lemieux, Gilles
    Officer                    279,350       25,000      329,350          0.1

    Paré, Lyne
    Officer                     50,000       25,000      100,000         0.03
                            ----------   ------------------------------------
    Total                   30,620,920   13,875,000   58,370,920         20.2
    

Contacts

Haemacure Corporation: Joseph Galli
Chairman and CEO
(514) 990-7074
jgalli@haemacure.ca
www.haemacure.com

Diane Roch
Director
Communications and Investor Relations
(514) 282-3350 ext. 27
Cell: (514) 952-3350
droch@haemacure.ca

Gilles Lemieux
Corporate Secretary
(514) 282-3350 ext. 22
Cell: (514) 968-1382
glemieux@haemacure.ca.

The Investor Forum will webcast the audio portion of the presentation and post the associated slides via its website at www.investorcalendar.com/ClientPage.... hosted by PrecisionIR. To access the live broadcast via internet in listen-only mode, or the subsequently archived recording, simply cut and paste the abovementioned link or http://www.investorcalendar.com/ directly into your web browser.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

SOURCE: Haemacure Corporation

Haemacure Corporation

Joseph Galli Chairman and CEO

(514) 990-7074

Email: jgalli@haemacure.ca

Diane Roch Director, Communications

(514) 282-3350 ext. 27 or Cell.: (514) 952-3350

Email: droch@haemacure.ca

Website: www.haemacure.com

Joseph Galli, Chairman and CEO,

(514) 990-7074

jgalli@haemacure.ca

or

Diane Roch, Director, Communications,

(514) 282-3350 ext. 27, Cel.: (514) 952-3350

droch@haemacure.ca

www.haemacure.com

Montreal, Quebec, April 28, 2008 – Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announced today the appointment of two senior managers to its management team.

To further strengthen the Company’s growing presence in the plasma fractionation industry, Haemacure has appointed Ms. Dawn Benson as Director of Quality Assurance and Quality Control and Mr. Kenneth P. Smith as Director of Manufacturing. Both Ms. Benson and Mr. Smith will work from Haemacure’s manufacturing facility located in Sarasota, Florida.

Before joining Haemacure, Ms. Benson spent over 10 years in the quality assurance and quality control fields, having held quality assurance positions at several health care, consumer products and plasma fractionation companies.

Mr. Smith brings to the team over 15 years of experience in the areas of production and supervision, most recently with another plasma fractionation company.

In addition to the senior managers hire, Haemacure has also staffed the production and laboratory teams necessary to commission the manufacturing facility.

“We are very excited to welcome all the new members of our growing team. Their valuable expertise will no doubt greatly contribute to achieving the milestones of commissioning our new manufacturing facility by mid-2008 and having a first patient undergo surgery in our planned pivotal Phase ll/Phase lll clinical trials during the first quarter of 2009,” said Joseph Galli, Chairman and Chief Executive Officer of Haemacure. “We look forward to their contribution in insuring that Haemacure meets its milestones and value creation objectives” concluded Mr. Galli.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel®HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

For Information:

Haemacure Corporation

Joseph Galli

Chairman and CEO

Tel: 514-990-7074

jgalli@haemacure.ca

Diane Roch

Director, Communications

Tel: 514-282-3350 ext. 27

droch@haemacure.ca

www.haemacure.com

Link:

http://www.agoracom.com/executive/ha...

Regards,

AGORACOM Investor Relations

MONTREAL, April 10  - Haemacure Corporation (TSX: HAE.TO), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, disclosed today the results of a preclinical study it recently conducted on the use of its proprietary lead product candidate, the human fibrin sealant Hemaseel(R)HMN, in preventing the formation of post-surgical adhesions.

The study was conducted on 16 rabbits that underwent open gynaecologic surgery in a uterine horn model. In preclinical testing, Hameacure's fibrin sealant was found to be significantly superior to the control group in preventing the formation of post-surgical tissue adhesion. It was also found to be superior to historical data disclosed in published literature for GYNECARE INTERCEED(TM)(TC7) Absorbable Adhesion Barrier, marketed by Ethicon, Inc.

These preclinical results are strategically significant as Haemacure's current fibrin sealant haemostasis formulation was used in this study. Initial analysis indicates that no change in the formulation or the manufacturing of Haemacure's fibrin sealant will be required to pursue an adhesion prevention indication. The safety and manufacturing information applicable to an IND to conduct adhesion prevention trials using Haemacure's fibrin sealant is identical to the information that will be included in the IND amendment to be filed later this year for the haemostasis indication. It is likely that adhesion prevention-specific preclinical data, clinical protocols and programs will also be required.

The use of Haemacure's current fibrin sealant haemostasis formulation for adhesion prevention could significantly accelerate time to market for this indication, by three to five years. This reduced timeframe accelerates Haemacure's ability to address a significant unmet medical need with an additional indication for its fibrin sealant. Post-surgical adhesions are estimated to cost the U.S. healthcare system in excess of $2.1 billion annually. The U.S. market for adhesion prevention products is estimated today at $100 million and could grow to US$150-200 milion in fibrin sales.

Post-surgical tissue adhesion is a significant clinical problem within every surgical specialty. It is a disorder in which tissues that should remain separated in the body adhere to each other. Adhesions are a major cause of infertility, bowel perforation, small bowel obstruction, chronic abdominal and pelvic pain, and have been associated with patient mortality.

Liquid fibrin sealants, such as Haemacure's, are much easier to apply to treatment sites than adhesion barriers such as Interceed(TM). They also lend themselves to laparoscopic application much better than these types of barriers.

"We are very excited with the results of this study, as it opens a new market with a significant unmet medical need and allows Haemacure to leverage to leverage its technology, past clinical data and experience in a timely manner" said Joseph Galli, Chairman and Chief Executive Officer of Haemacure. "This initiative demonstrates our commitment to leverage our assets, people and technology to create shareholder value and reduce risk."; concluded Mr. Galli.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combinations with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Contacts

Haemacure Corporation: Joseph Galli

Chairman and CEO

(514) 990-7074

jgalli@haemacure.ca

www.haemacure.com

Diane Roch

Director

Communications and Investor Relations

(514) 282-3350 ext. 27

Cell: (514) 952-3350

droch@haemacure.ca

Results of Preclinical Study of Fibrin Sealant in Adhesion Prevention

Haemacure presented the positive results of a preclinical study it recently conducted on the use of the current formulation of its proprietary lead product candidate, the human fibrin sealant Hemaseel(R)HMN. Haemacure's fibrin sealant proved superior to the untreated control subjects in open surgery in preventing the formation of post-surgical adhesions. It also proved to be superior to the data found in published literature for GYNECARE INTERCEED(TM) (TC7) Absorbable Adhesion Barrier, marketed by Ethicon, Inc. Haemacure plans on expanding the fields of use for its fibrin sealant by entering the adhesion prevention market, thanks to the leveraging of the current formulation of its fibrin sealant. Post-surgical adhesions are estimated to cost the U.S. healthcare system US$2.1 billion annually.

New Manufacturing Facility on Schedule and on Budget

Haemacure reported that the construction of its small scale manufacturing facility in Sarasota, Florida is progressing on schedule and on budget. The targeted completion date is mid-2008, as planned. The construction of a small-scale facility is the first phase of Haemacure's two-phase strategy to significantly reduce the cost of meeting its First-Patient-In objective during the first quarter of 2009. The second phase of the strategy consists in expanding the facility during the review of its license applications by regulatory authorities, and in completing the development of Haemacure's second product candidate, the Hemaseel(R)Thrombin active hemostatic agent. Haemacure's fibrin sealant for adhesion prevention will also be manufactured in this facility.

Strategic Hires

Haemacure announced the hiring of a Director of Manufacturing and a Director of Quality Assurance and Quality Control. This brings to five the number of senior managers Haemacure has hired since the fall of 2007.

"We have made tremendous progress since we re-started Haemacure 14 months ago. We are on track to having a manufacturing facility online mid-2008 and having a first patient undergo surgery in our pivotal Phase II/Phase III clinical trials during the first quarter of 2009. We are also now able to attract high-calibre senior managers from the plasma fractionation industry." said Joseph Galli, Chairman and Chief Executive Officer of Haemacure. "We are confident we will deliver on the objectives we had set for ourselves when we refinanced Haemacure, including leveraging our assets in fields such as adhesion prevention. We look forward to making Haemacure a fully independent global haemostasis player.", concluded Mr. Galli.

Key Milestones

Haemacure also highlighted key milestones to be achieved in the next

three quarters:

- Completion of the manufacturing facility by mid-2008

- Production of fibrin sealant for pivotal Phase II/and Phase III

clinical trials by Q3/08

- Approval of amendment of IND by the US FDA to launch clinical trials

for fibrin sealant

- Launch of clinical trials in Q1/09

- Entering into of partnerships and collaborations

Board of Directors

Haemacure announced that the shareholders elected the seven nominees for election as directors.

Shareholder Rights Plan

At the annual meeting of shareholders of the Corporation, the shareholders approved the renewal of the Shareholders Rights Plan. The Plan provides for the equal treatment of all shareholders of the Corporation.

The Rights are designed to provide additional protection against abusive takeover tactics such as partial tender offers, selective open-market purchases and offers for all the shares of the Corporation at less than full value or at an inappropriate time. The Rights are intended to assure that the Board of Directors has the ability to protect shareholders and the Corporation if attempts are made to gain control of the Corporation in a manner that is not in the best interests of the Corporation and all of its shareholders.

The approved continuation of the Corporation's Rights Plan means that all common shares of the Corporation issued or to be issued will be accompanied by one Right. The Rights will be exercisable only if a person or group acquires 20% or more of the Corporation's common shares or announces an offer not in accordance with certain requirements, the consummation of which would result in the ownership by a person or group of 20% or more of the common shares. Upon a person or group owning 20% or more of the Corporation's common shares, each shareholder will be entitled to purchase, for each common share of the Corporation he or she may have, and at the Right's exercise price, a number of common shares of the Corporation having a market value at the time of twice the Right's exercise price. The exercise price is set at $100 and may be adjusted, depending on certain circumstances. Unless continued, the Plan will expire on April 26, 2011.

Webcast Details

A replay of Haemacure's Annual General and Special Meeting of Shareholders is available on the Company's website at www.haemacure.com.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combinations with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Contacts

Haemacure Corporation: Joseph Galli

Chairman and CEO

(514) 990-7074

jgalli@haemacure.ca

www.haemacure.com

Diane Roch

Director

Communications and Investor Relations

(514) 282-3350 ext. 27

Cell: (514) 952-3350

droch@haemacure.ca

Presentation

Mr. Joseph Galli, Chairman and Chief Executive Officer of Haemacure, will report on accomplishments of 2007 and provide an outlook for 2008 and beyond, including a report on Haemacure's clinical programs for its two proprietary, human product candidates, a fibrin sealant and an active, topical hemostatic agent (thrombin).

Live Webcast

For those who are unable to attend in person, Haemacure will simultaneously host a live webcast of the presentation with slides, at

http://events.snwebcastcenter.com/haemacure/20080409/

MONTREAL, Apr 8, 2008 -- Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization, will hold its Annual General and Special Meeting of Shareholders on:

Mr. Joseph Galli, Chairman & CEO of Haemacure, will report on Haemacure's projects, recent developments and future outlook. Mr. Galli will also present an overview of the current clinical programs for Haemacure's proprietary fibrin sealant and hemostatic agent product candidates, construction of the Company's new manufacturing facility and growth potential.

Live Webcast

For those who are unable to attend in person, Haemacure will simultaneously host a live webcast with slides of Mr. Galli's presentation at http://events.snwebcastcenter.com/haemacure/20080409/

About Haemacure Corporation

Haemacure Corporation is a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a human-derived fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is human thrombin, a component of its fibrin sealant, now in preclinical stage. Both candidates have applications in the expanding bio-surgical market. Follow-on development will focus on surgical haemostats, wound management, drug delivery, regenerative medicine, adhesion prevention and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these specialty proteins and enzymes through partnerships with pharmaceutical and biotechnology companies.

SOURCE: Haemacure Corporation

to coordinate interviews, please contact:

Diane Roch, Director of Communications,

(514) 282-3350, x27, Mobile: (514) 952-3350,

droch@haemacure.ca,

www.haemacure.com,

RSVP: droch@haemacure.ca